Communiqués Apollomics, Inc.

Actions

APLM

KYG0411D1236

Sociétés holdings

Temps Différé Nasdaq Autres places de cotation 22:30:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
17,24 ^USD	-0,61%		-4,19%	-7,76%

21/07	Apollomics Inc. annonce des changements au sein de son conseil d'administration et de ses comités, effectifs au 20 juillet 2026	CI
24/06	Apollomics reçoit un avis de non-conformité du Nasdaq concernant l'exigence de capitalisation boursière	MT

Communiqués

13/07	Apollomics Regains Full Compliance with Nasdaq Listing Requirements	AQ
24/06	Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia	AQ
27/04	Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress	AQ
01/04	Apollomics Inc. Announces $2.0 Million Bridge Financing	AQ
22/12	Apollomics Reports First Half 2025 Financial Results	AQ
19/11	Apollomics Announces Settlement of Cayman Litigation	AQ
18/11	Apollomics Announces Changes to its Board of Directors and Composition of Committees	AQ
15/10/25	Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation	AQ
14/10/25	Nasdaq Resumes Trading in Apollomics Inc.	AQ
14/10/25	Apollomics, Inc. Company Operational Continuity Update	AQ
23/09/25	Apollomics : Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain	PU
17/09/25	Nasdaq Halts Apollomics Inc., Ltd.	AQ
03/04/25	Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress	AQ
31/03/25	Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib	AQ
23/12/24	Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia	AQ
20/12/24	Apollomics : Announces Top line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia Form 6 K	PU
20/12/24	Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia	AQ
11/12/24	Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement	AQ
10/12/24	Apollomics : Regains Compliance with Nasdaq's Minimum Bid Price Requirement Form 6 K	PU
10/12/24	Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	AQ
22/11/24	Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split	AQ
21/11/24	Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split	AQ
21/11/24	Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split	GL
15/11/24	Apollomics : Results of the 2024 Extraordinary General Meeting of Shareholders Form 6 K	PU
01/11/24	Apollomics : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 14, 2024 Form 6 K	PU